Author Archives: admin


Stem Cell Clinic > Articles by: admin

Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

By Uncategorized

PUBLIC RELEASE DATE:

20-Oct-2014

Contact: David McKeon 212-365-7440 New York Stem Cell Foundation @nyscf

Leaders in translational stem cell research from around the world will present the latest advances in stem cell science that are leading to better treatments and cures to disease and injury at The New York Stem Cell Foundation's Ninth Annual Translational Stem Cell Research Conference.

The opening day of the conference includes a panel discussion on large scale, big data stem cell and genetic initiatives moderated by Susan L. Solomon, JD, CEO and Co-founder of The New York Stem Cell Foundation (NYSCF), with panelists George Church, PhD, Harvard Medical School; John Greally, PhD, Albert Einstein College of Medicine; Scott Noggle, PhD, The NYSCF Research Institute; and Eric Schadt, PhD, the Icahn School of Medicine at Mount Sinai.

Later that day, a discussion on neurodegeneration includes Kevin Eggan, PhD, Harvard University and the NYSCF Research Institute, who will discuss his research identifying an existing drug candidate that may be of use treating ALS and is entering clinical trials in the coming year. The following session on cell reprogramming and cancer includes Michael Milone, MD, PhD, University of Pennsylvania, who will discuss recent research results from his lab and his colleagues including the results of a clinical trial for leukemia featured in The New York Times last week. The first day closes with a conversation on personalized medicine featuring Dieter Egli, PhD, NYSCF Robertson Investigator at the NYSCF Research Institute and Columbia University; Rudolf Jaenisch, MD, The Whitehead Institute; and Sir Ian Wilmut, FRS, FRSE, University of Edinburgh.

On October 23, the day will begin with remarks by Kenneth Adams and Kyle Kimball, President of the Empire State Development Corporation and President of the New York City Economic Development Corporation, respectively. The session on translating innovation from the laboratory to the clinic features Stephen Chang, PhD, of the NYSCF Research Institute and Richard Pearse, PhD, of the Harvard Catalyst and eagle-i Network who will discuss their collaboration on the first publicly available induced pluripotent stem cell database. The day will close with a presentation on induced neuronal cells and cell transdifferentiation from the 2014 NYSCF Robertson Stem Cell Prize recipient, Marius Wernig, MD, PhD, of Stanford University School of Medicine.

Sir Ian Wilmut will give the keynote address on October 22nd and Dr. Rudolf Jaenisch will give the keynote address on the last day of the conference.

The full conference agenda can be found at http://www.nyscf.org/conference

###

See more here:
Stem cell and clinical research advances to be presented at NYSCF's Ninth Annual Conference

Stem Cell Hair Therapy – Hair Regrowth Treatment using Adult Stem Cell from Luminesce – Video

By Stem Cell Treatment


Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce
Do It Yourself - Stem Cell Hair Therapy : http://placesiana.com/stem-cell-hair-loss-therapy Imagine becoming a healthier, much younger, better looking you? Infused with a potent growth factor...

By: Sam Jeunesse

Go here to see the original:
Stem Cell Hair Therapy - Hair Regrowth Treatment using Adult Stem Cell from Luminesce - Video

Stem cell treatment of spinal cord injuries [Pharyngula]

By Stem Cell Treatment

I have to admit that my first response to these reports out of Britain that stem cells had been successfully used to repair a complete spinal cord transection was skepticism incredulity even. Theyre reporting that a man with a completely severed spinal cord at level T10-T11 is able to walk again! The Guardian gushes! The Daily Mail gets in the act (always a bad sign)! When I read that the patient had an 8mm gap in his spinal cord that had been filling up with scar tissue for the last two years, I was even more doubtful: under the best of conditions, it was unlikely that youd get substantial connectivity across that distance.

So I read the paper. Im less skeptical now, for a couple of reasons. They actually did this experiment on 3 people, and all showed degrees of improvement, although the newspapers are all focusing on just the one who had the greatest change. The gradual changes are all documented thoroughly and believably. And, sad to say, the improvements in the mans motor and sensory ability are more limited and more realistic than most of the accounts would have you think.

The story is actually in accord with what weve seen in stem cell repair of spinal cord injury in rats and mice.

Overall, they found that stem cell treatment results in an average improvement of about 25% over the post-injury performance in both sensory and motor outcomes, though the results can vary widely between animals. For sensory outcomes the degree of improvement tended to increase with the number of cells introduced scientists are often reassured by this sort of dose response, as it suggests a real underlying biologically plausible effect. So the good news is that stem cell therapy does indeed seem to confer a statistically significant improvement over the residual ability of the animals both to move and feel things beyond the spinal injury site.

Significant but far from complete improvement is exactly what wed expect, and that improvement is a very, very good thing. It is an accomplishment to translate animal studies into getting measurable clinical improvements in people.

The basic procedure is straightforward. There is a population of neural cells in humans that do actively and continuously regenerate: the cells of the olfactory bulb. So what they did is remove one of the patients own olfactory bulbs, dissociate it into a soup of isolated cells, and inject them into locations above and below the injury. They also bridged the gap with strips of nerve tissue harvested from the patients leg. The idea is that the proliferating cells and the nerves would provide a nerve growth-friendly environment and build substrate bridges that would stimulate the damaged cells and provide a path for regrowth.

Big bonus: this was an autologous transplant (from the patients own tissues), so there was no worry about immune system rejection. There were legitimate worries about inflammation, doing further damage to the spinal cord, and provoking greater degeneration, and part of the purpose of this work was to assess the safety of the procedure. There were no complications.

Also, Im sure you were worried about this, but the lost olfactory cells also regenerated and the patients completely recovered their sense of smell.

Now heres the clinical assessment. Three patients were operated on; T1 is the one who has made all the news with the most remarkable improvement. There were also three control patients who showed no improvement over the same period.

Neurological function improved in all three transplant recipients (T1, T2, T3) during the first year postsurgery. This included a decrease of muscle spasticity (T1, T2) as well as improvement of sensory (T1, T2, T3) and motor function (T1, T2, T3) below the level of spinal cord injury.

Read this article:
Stem cell treatment of spinal cord injuries [Pharyngula]

StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

By Stem Cell Treatment

La Jolla, CA (PRWEB) October 21, 2014

StemGenex, the leading resource for adult adipose stem cell therapy in the US aimed at improving the lives of patients dealing with degenerative diseases today announced their newest clinical study in partnership with Stem Cell Research Centre for Osteoarthritis. StemGenex and Stem Cell Research Centre (SCRC) believe that a commitment to the safety and efficacy of stem cell therapy are paramount when providing care to patients with life threatening diseases.

There are currently 21 million people in the U.S. alone, who suffer from Osteoarthritis. The most common symptoms are joint pain and stiffness which most commonly affect the neck, lower back, knees, shoulders and hips. These symptoms gradually worsen over time ultimately leading to the need for a total joint replacement procedure. StemGenex believe their new clinical study may provide patients improved mobility, significantly reduced pain and ultimately a better quality of life without needing joint replacement surgery.

This clinical study makes stem cell therapy for osteoarthritis accessible to the millions of individuals currently struggling with this painful disease. The protocol used in these stem cell treatments is unique to StemGenex and SCRC, having the possibility of being more effective than other stem cell treatments currently available. These treatments will utilize a multiple administration method which also includes injections precisely targeting the joint space. StemGenex believes these treatments may be able to keep patients from needing joint replacement surgery in the future, due to regeneration of cartilage in the joint.

This clinical study will be conducted under the leadership of the principal investigator,Dr. Jeremiah McDole, Ph.D. Dr. McDole states, We are excited to begin enrolling for this new study. We have high expectations for what we will learn and what advancements can ultimately be implemented. Of course, our focus is always set toward the near future and what can be done to help improve the lives of those individuals with Osteoarthritis.

This study is registered through The National Institutes of Health which can be found at http://www.clinicaltrials.gov and is being conducted under IRB approval of Stem Cell Research Centre (SCRC). There are many patients who are exploring stem cell therapy for osteoarthritis and it is important they have access to top-tier stem cell therapy. By providing patients access to stem cell studies registered through The National Institutes of Health, patients now have the ability to choose treatment that focuses on both safety and efficacy.

Rita Alexander, founder and president of StemGenex stated With so many people suffering from Osteoarthritis its absolutely wonderful to provide a treatment that has not only shown efficacy but also to be minimally invasive. Over the last several years we have observed significant improvement in the symptoms of Osteoarthritis patients through stem cell treatment. Through these registered clinical studies, we will now be able to publish our findings over the next few years.

This clinical study follows on the heels of StemGenex latest clinical studies for both Parkinsons disease and Multiple Sclerosis. Stem cell treatment studies are currently being offered by StemGenex partnering with Stem Cell Research Centre (SCRC) to patients diagnosed with Osteoarthritis as well as degenerative neurological diseases. StemGenex takes a unique approach of compassion and empowerment while providing access to the latest stem cell therapies for degenerative conditions including Multiple Sclerosis, Alzheimers disease, stroke recovery and others.

To find out more about stem cell therapy, contact StemGenex either by phone at (800) 609-7795 or email Contact@stemgenex.com

See the article here:
StemGenex New Clinical Study Aims to Provide Relief to Osteoarthritis Patients through Latest Stem Cell Therapy

Scientists grow human intestine giving hope to people with gut problems and cancer patients

By Stem Cell Doctors

Tissue fragments called organoids were transplanted into mice and matured Mice produced 'significantamounts of fully-functioning human tissue Study gives experts new way to study conditions causing intestinal failure Step towards growing tissues that could replace damaged human intestine

By Sarah Griffiths for MailOnline

Published: 07:24 EST, 20 October 2014 | Updated: 08:07 EST, 20 October 2014

141 shares

12

View comments

Scientists have managed to grow a piece of human intestine in the laboratory,paving the way for new treatments for gut disorders such as Crohn's disease and even cancer.

The breakthrough was made using adult stem cells, which the researchers used to growtissue fragments called organoids.

These are three-dimensional organ 'buds' with the potential to develop into tissues with certain functions.

Breakthrough:Functioning human intestine has been grown from stem cells in the laboratory, paving the way to new treatments for gut disorders. A stock image showing the transfer of fluid into a petri dish containing stem cells for medical image is pictured

Excerpt from:
Scientists grow human intestine giving hope to people with gut problems and cancer patients

Progeny 'mega cells' pivotal in adult stem cell transplant

By Stem Cell Medicine

A new research has identified that 'megakaryocytes' or 'megacells' are responsible for playing a critical role in adult stem cell transplant.

Hematopoietic stem cells differentiate to generate megakaryocytes in bone marrow and the study has shown that the hematopoietic stem cells (the parent cells) could be directly controlled by their own progeny (megakaryocytes).

The results had suggested that megakaryocytes might be used clinically to facilitate adult stem cell regeneration and to expand cultured cells for adult stem cell transplants.

Researchers at Stowers Institute for Medical Research had discovered that megakaryocytes had directly regulated the function of murine hematopoietic stem cellsadult stem cells that had formed the blood and immune cells and that had constantly renewed the body's blood supply. These cells could also develop into all types of blood cells, including white blood cells, red blood cells, and platelets.

Because of their remarkable ability to renew themselves and differentiate into other cells, hematopoietic stems cells have been used to treat many diseases and conditions. The transplantation of isolated human hematopoietic stem cells has been used in the treatment of anemia, immune deficiencies and other diseases, including cancer.

The study was published in the journal Nature Medicine.

(Posted on 20-10-2014)

Post your comments

Information on States of India:

Read the rest here:
Progeny 'mega cells' pivotal in adult stem cell transplant

UC San Diego Health System announces human testing of stem cell therapies

By Stem Cell Medical Center

SAN DIEGO (CNS) - UC San Diego Health System announced Monday that human testing of injected neural stem cell therapies are underway at its Sanford Stem Cell Clinical Center.

Researchers are conducting three different trials -- one on a 26-year-old woman paralyzed after a traffic crash, and others on diabetes and leukemia patients.

"What we are seeing after years of work is the rubber hitting the road," said Lawrence Goldstein, director of the UC San Diego Stem Cell program and Sanford Stem Cell Clinical Center.

"These are three very ambitious and innovative trials," he said. "Each followed a different development path -- each addresses a very different disease or condition. It speaks to the maturation of stem cell science that we've gotten to the point of testing these very real medical applications in people."

The first tests are being made with low doses in order to ensure the safety of the patients, Goldstein said.

Working with Maryland-based Neuralstem Inc., neural stem cells were injected into the site of the paralyzed woman's spinal cord injury on Sept. 30, and she is recovering at home without complications or adverse effects, said Dr. Joseph Ciacci, a neurosurgeon at UC San Diego Health System. Her name was not released.

The researchers hope that the transplanted cells will develop into neurons that bridge the gap created by the injury, replace severed or lost nerve connections and restore at least some motor and sensory function. According to UCSD, testing in laboratory rats with spinal cord injuries were promising.

A two-year trial on about 40 Type 1 diabetes patients will involve implanting cells under the skin that were derived from embryonic stem cells, with the hope they will safely mature into pancreatic beta and other cells able to produce a continuous supply of needed insulin and other substances, according to the researchers. The first procedure is expected to take place sometime this month, according to UCSD.

Type 1 diabetes, which usually onsets during childhood and has no cure, causes the pancreas to produce little or no insulin. Patients have to inject insulin daily and rigorously manage their diet and lifestyle.

The third trial will involve a potential drug to fight chronic lymphocytic leukemia, the most common form of blood cancer in adults. Patients in the test will receive the drug via an intravenous infusion every 14 days at the UCSD Moores Cancer Center.

See the original post:
UC San Diego Health System announces human testing of stem cell therapies

UCSD Stem Cell program begins human testing

By Stem Cell Medical Center

SAN DIEGO (CNS) - UC San Diego Health System announced Monday that human testing of injected neural stem cell therapies are underway at its Sanford Stem Cell Clinical Center.

Researchers are conducting three different trials -- one on a 26-year-old woman paralyzed after a traffic crash, and others on diabetes and leukemia patients.

"What we are seeing after years of work is the rubber hitting the road," said Lawrence Goldstein, director of the UC San Diego Stem Cell program and Sanford Stem Cell Clinical Center.

"These are three very ambitious and innovative trials," he said. "Each followed a different development path -- each addresses a very different disease or condition. It speaks to the maturation of stem cell science that we've gotten to the point of testing these very real medical applications in people."

The first tests are being made with low doses in order to ensure the safety of the patients, Goldstein said.

Working with Maryland-based Neuralstem Inc., neural stem cells were injected into the site of the paralyzed woman's spinal cord injury on Sept. 30, and she is recovering at home without complications or adverse effects, said Dr. Joseph Ciacci, a neurosurgeon at UC San Diego Health System. Her name was not released.

The researchers hope that the transplanted cells will develop into neurons that bridge the gap created by the injury, replace severed or lost nerve connections and restore at least some motor and sensory function. According to UCSD, testing in laboratory rats with spinal cord injuries were promising.

A two-year trial on about 40 Type 1 diabetes patients will involve implanting cells under the skin that were derived from embryonic stem cells, with the hope they will safely mature into pancreatic beta and other cells able to produce a continuous supply of needed insulin and other substances, according to the researchers. The first procedure is expected to take place sometime this month, according to UCSD.

Type 1 diabetes, which usually onsets during childhood and has no cure, causes the pancreas to produce little or no insulin. Patients have to inject insulin daily and rigorously manage their diet and lifestyle.

The third trial will involve a potential drug to fight chronic lymphocytic leukemia, the most common form of blood cancer in adults. Patients in the test will receive the drug via an intravenous infusion every 14 days at the UCSD Moores Cancer Center.

Here is the original post:
UCSD Stem Cell program begins human testing

Scientists Grow, Implant Human Intestinal Tissue in Mice

By Stem Cell Medical Center

SUNDAY, Oct. 19, 2014 (HealthDay News) -- New stem cell-based research could improve understanding of intestinal diseases and eventually lead to new treatments, a new study suggests.

Scientists used stem cells to grow "organoids" of functioning human intestinal tissue in a lab dish. They then transplanted the organoids into mice, creating a new model for studying intestinal disorders, according to the researchers.

"This provides a new way to study the many diseases and conditions that can cause intestinal failure, from genetic disorders appearing at birth to conditions that strike later in life, such as cancer and Crohn's disease," lead investigator Dr. Michael Helmrath, surgical director of the Intestinal Rehabilitation Program at the Cincinnati Children's Hospital Medical Center, said in a center news release.

"These studies also advance the longer-term goal of growing tissues that can replace damaged human intestine," he added.

Further research could eventually lead to the ability to create personalized human intestinal tissue to treat gastrointestinal diseases, according to the researchers.

"These studies support the concept that patient-specific cells can be used to grow intestine," Helmrath explained.

The research was published online Oct. 19 in the journal Nature Medicine.

The intestinal organoids were created using so-called pluripotent stem cells, which can become any type of tissue in the body. The scientists created these "blank" stem cells by reprogramming adult cells taken from skin and blood samples.

The stem cells were placed in lab dishes with a specific molecular mixture that prompted the cells to grow into intestinal organoids, which developed into fully mature, functioning human intestinal tissue after being transplanted into mice.

The mice were genetically engineered so that their immune systems would not reject the human tissue, the study authors noted.

Read more here:
Scientists Grow, Implant Human Intestinal Tissue in Mice

→←